DOI: 10.1055/s-00000094

Zeitschrift für Gastroenterologie


Modest DP. et al.
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer.

J Clin Oncol 2015;
33: 3718-3726

Download Bibliographical Data

Search in: